Model diagnostics for old death events. by Xin Zhang (35492)

Model diagnostics for adult death events. by Xin Zhang (35492)

Model diagnostics for child death events. by Xin Zhang (35492)

Model diagnostics for all death events. by Xin Zhang (35492)

Model diagnostics for female death events. by Xin Zhang (35492)

Model diagnostics for male death events. by Xin Zhang (35492)

T3SS induction slows growth, but cells can support high levels of S10 expression. by Justin Greene (306625)

Data supporting this article. by Karel Joineau (21799908)

“…Clinical variables did not significantly differed between FR and SM groups. Mean VAS decreased by −12.3 mm ± 15.2 in FR group (n = 15) and −17.9 mm ± 29.4 in SM group (n = 15). …”

Demographic and clinical data at baseline. by Karel Joineau (21799908)

“…Clinical variables did not significantly differed between FR and SM groups. Mean VAS decreased by −12.3 mm ± 15.2 in FR group (n = 15) and −17.9 mm ± 29.4 in SM group (n = 15). …”

Changes in clinical variables. by Karel Joineau (21799908)

“…Clinical variables did not significantly differed between FR and SM groups. Mean VAS decreased by −12.3 mm ± 15.2 in FR group (n = 15) and −17.9 mm ± 29.4 in SM group (n = 15). …”

Supplementary file 1_Disproportionality analysis of taste disorders using the FDA adverse event reporting system and Japanese adverse drug event report databases.docx by Yoji Kyotani (599686)

“…The hazard for clarithromycin remained constant throughout administration, while the hazards for the other drugs decreased over time. Logistic regression analysis confirmed significant associations between the drugs and taste disorders, even after adjusting for age and sex. …”

Table1_Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.docx by Yanjing Zhang (401134)

“…</p>Methods<p>AE reports in the FDA Adverse Event Reporting System (FAERS) from 2019 Q4 (FDA approval of Lumateperone) to 2024 Q1 were collected and analyzed. …”

Changes in global brain blood volume mediate CSF in- and outflux. by Juliana Zimmermann (10507091)

Global-GM and CSF fMRI signals during steady-state conditions. by Juliana Zimmermann (10507091)

KSHV lytic replication enhanced PML-IKKε interaction and disrupted PML NBs in BCBL-1 cells. by Xiaoqian Wang (460263)

IKKε interacts with PML and disrupts the PML nuclear bodies. by Xiaoqian Wang (460263)

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”